News

Under the terms of the agreement, Caladrius acquired the exclusive worldwide rights to the data set and regulatory filings for the CD34+ cell therapy program for the treatment

These trials will evaluate the effect of Jardiance on exercise ability and heart failure symptoms in people with chronic heart failure independent of whether they have type 2

The regulator approved Opdivo label update offering flexible flat-dosing options every two weeks (240 mg) or every four weeks (480 mg). Opdivo, which is a programmed death-1 (PD-1) inhibitor, was

The submission acceptance is based on Phase III data from the DEPICT (Dapagliflozin Evaluation in Patients with Inadequately Controlled Type 1 Diabetes) clinical programme for Forxiga in T1D.

The multi-year collaboration is focused on the identification and development of unique small molecules against targets for a range of oncology, inflammatory and neurodegenerative indications. The collaboration is

The drug was tested in the Clareos-1 and Clareos-2 trials, which featured over 1,500 patients, aged nine years and older with moderate-to-severe acne vulgaris. Olumacostat glasaretil was evaluated

Per the Prescription Drug User Fee Act, the target action date is October 20, 2018. Dupixent is a human monoclonal antibody specifically designed to inhibit signaling of interleukin-4

Mylan anticipates introducing Symfi Lo in the coming weeks and Cimduo in the second quarter of this year. These upcoming launches will extend Mylan's global antiretroviral (ARV) platform

The European Medicines Agency (EMA) has started an Article 20 referral procedure after reports of inflammatory encephalitis and meningoencephalitis. Seven cases of serious inflammatory brain disorders including encephalitis and meningoencephalitis